National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
Quick Links
Director's Corner
Updates from the Director

Dictionary of Cancer Terms
Cancer-related terms

NCI Drug Dictionary
Definitions, names, and links

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

Advisory Boards and Groups
Information, meetings, reports

Science Serving People
Learn more about NCI

Español
Información en español
Quit Smoking Today
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

HLA-A2, A3-restricted FGF-5 peptides/Montanide ISA-51 vaccine
A peptide vaccine comprised of synthetic HLA-A2- and HLA-A3-binding peptides, derived from amino acid sequences of fibroblast growth factor-5 (FGF-5), combined with the adjuvant Montanide ISA-51 with potential antineoplastic activity. HLA-A2, A3-restricted FGF-5 peptides contain motifs recognized by the MHC class I molecules HLA-A2 and HLA-A3 and may stimulate a cytotoxic T-cell response against tumor cells that overexpress FGF-5. Montanide ISA-51 (also known as incomplete Freund's adjuvant or IFA), a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant, non-specifically stimulates cell-mediated immune responses to antigens. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Abbreviation:HLA-A2A3-FGF5-ISA51



Previous:high-selenium Brassica juncea, Hiltonol, Hivid, HLA-A*2402-restricted URLC10-TTK-VEGFR1-VEGFR2 multipeptide vaccine, HLA-A1, A2, B35-restricted survivin peptides/Montanide ISA-51 vaccine
Next:Hodgkin's antigens-GM-CSF-expressing cell vaccine, HPPH, HPV 16 E7:86-93 peptide vaccine, HPV L1 VLP vaccine V504, Hsp27 antisense oligonucleotide OGX-427

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov